Abstract
Objective
To detect the anticoagulation and antiplatelet effects of different concentrations of puerarin, heparin sodium and tirofiban hydrochloride on the blood samples of healthy volunteers by Sonoclot coagulation and platelet function analyzer.
Methods
Peripheral blood samples were extracted from 20 healthy volunteers, followed by adding different concentrations of puerarin, heparin sodium and tirofiban hydrochloride. Samples were detected for activated clotting time (ACT), clot rate (CR) and platelet function (PF) by Sonoclot coagulation and platelet function analyzer instrument.
Results
For puerarin and heparin sodium, the values of ACT gradually increased, and the values of CR and PF gradually decreased with increasing in drug concentration. There was a linear (or log linear) relationship between ACT, CR, PF value and drug concentration (P<0.01). Corresponding to each value, a regression equation was obtained. For tirofiban hydrochloride, the values of ACT and CR had no significant changes, while PF values gradually decreased with concentration increasing. There was also a linear relationship between PF values and concentrations of tirofiban hydrochloride (P<0.01). Under the same ACT values, the puerarin corresponding CR values (CR = e−0.0062ACT+4.31, P<2.2e-16) were always higher than the corresponding values (CR = e−0.0028ACT+2.79, P-value<2.2e-16) of heparin sodium. For high concentrations of puerarin (e.g. 3.8 mg/600 μL) and tirofiban hydrochloride (e.g. 0.8 μg/600 μL), PF values had no significant difference. However, PF values for high puerarin concentration had a larger variance.
Conclusions
Puerarin has similar anticoagulant and antiplatelet effects with the heparin sodium, and may have a lower hemorrhage risk than heparin sodium when obtained the same anticoagulation effect in the concentration range of this experiment. In addition, for high concentration, puerarin had the same antiplatelet function as tirofiban hydrochloride but with a larger individual variability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yin ZZ, Zeng GY. Pharmacology of puerarin. V. Effects of puerarin on platelet aggregation and release of 5-HT from platelets. Acta Acad Med Sin (Chin) 1981;3 Suppl 1:44–47.
Tuman KJ, Spiess BD, Mccarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989;69:69–75.
Chapin JW, Becker GL, Hulbert BJ, Newland MC, Cuka DJ, Wood RP, et al. Comparison of thromboelastograph and Sonoclot coagulation analyzer for assessing coagulation status during orthotopic liver transplantation. Transplant Proc 1989;21:3539–3539.
John JD, William AL, AJ Wright. Effective hemostasis in cardiac surgery. Anesthesiology 1989;71:325–326.
Yang X. The study of development of purring injection [dissertation]. Changchun: Jilin University; 2008.
Chen X, Chen WZ, Zeng GY. Cardiovascular pharmacology. 3rd ed. Beijing: People’s Medical Publishing House; 2002:520–523.
Lynch JJ Jr, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther 1995;272:20–32.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the 1st-class General Financial Grant from the China Postdoctoral Science Foundation (No. 2016M590188)
Rights and permissions
About this article
Cite this article
Li, Sw., Feng, X., Xu, H. et al. Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study. Chin. J. Integr. Med. 24, 103–108 (2018). https://doi.org/10.1007/s11655-017-2419-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-017-2419-7